Amgen and Hospira Reach Settlement in Patent Dispute over Neupogen’s Biosimilar

shot by IP News Shots / 7:00 pm on 03 September, 2021

Amgen Inc. and Hospira have filed for a dismissal of a patent infringement lawsuit at the US District Court for the District of Delaware. Amgen had accused Hospira of infringing on their cancer drug patent with a biosimilar version of Neupogen.

Industry: Pharmaceuticals | Type of IP: Litigations

Read more at Bloomberg Law